ライフサイエンスコーパス: oral corticosteroid

1 rnase alfa, inhaled antibiotics, inhaled and oral corticosteroids).

2 Twelve patients (92.3%) received oral corticosteroid.

3 t patients by treatment with peri-infusional oral corticosteroid.

4 cy department services and/or treatment with oral corticosteroids.

5 old higher than in patients not treated with oral corticosteroids.

6 was time to first exacerbation that required oral corticosteroids.

7 ously received this treatment) and high-dose oral corticosteroids.

8 of NO inflammation, the latter responsive to oral corticosteroids.

9 mily history of hip fracture, and the use of oral corticosteroids.

10 infusions of cyclophosphamide, and high-dose oral corticosteroids.

11 The mainstay of therapy remains oral corticosteroids.

12 subjects, none of whom was taking inhaled or oral corticosteroids.

13 patients) required home oxygen treatment or oral corticosteroids.

14 defined mandatory taper to discontinue their oral corticosteroids.

15 d CCL-13 (MCP-4) in both asthma groups after oral corticosteroids.

16 bers of severe exacerbations and the dose of oral corticosteroids.

17 sthma who differed in molecular responses to oral corticosteroids.

18 4.1% anti-IgE, 10.7% theophylline, and 16.0% oral corticosteroids.

19 Twenty-two patients had NPs resistant to oral corticosteroids.

20 with nasal polyps (CRSwNP) are resistant to oral corticosteroids.

21 linical practice trigger the prescription of oral corticosteroids.

22 exacerbations were managed successfully with oral corticosteroids.

23 fety advantages over starting treatment with oral corticosteroids.

24 all prescriptions for asthma medication and oral corticosteroids.

25 versies in therapy, particularly the role of oral corticosteroids.

26 -14.34], theophylline: 2.46 [1.23-4.91], and oral corticosteroids: [2.99;.1.26-7.08]).

27 mong 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic

28 ial treatment responded, compared to 39% for oral corticosteroids, 36% for vigabatrin, and 9% for oth

29 t included antitubercular therapy (ATT) with oral corticosteroids (93 patients) or corticosteroids al

30 hich was averted in subsequent patients with oral corticosteroids administered during the infusion an

31 des of acute asthma requiring treatment with oral corticosteroids, admission, or a visit to an emerge

32 ynechiae (aHR, 5.9, P = .02), and the use of oral corticosteroid (aHR 28.9; P = .003) at the presenti

33 d and defined as short-course treatment with oral corticosteroids alone or in combination with an ant

34 ng asthma medications (particularly those on oral corticosteroids alone or in combination) were at en

35 Compared with oral corticosteroids alone, are oral antiviral drugs ass

36 Compared with oral corticosteroids alone, the addition of acyclovir, v

37 The median daily dose of oral corticosteroids among the 165 patients receiving or

38 Oral corticosteroid and antifungal therapies appear to b

39 ow-release oral theophylline are added, with oral corticosteroids and anti-immunoglobulin E treatment

40 It demonstrated that, when used properly, oral corticosteroids and immunosuppression can be given

41 Thus, oral corticosteroids and immunosuppression may be a pref

42 veness trial comparing systemic therapy with oral corticosteroids and immunosuppression with regional

43 h-dose inhaled corticosteroids combined with oral corticosteroids and long-acting beta2-agonists) wer

44 al follow-up and were primarily managed with oral corticosteroids and other immunosuppressive agents.

45 Dispensation of oral corticosteroids and rate of asthma exacerbations we

46 bgroup analysis of patients not on long-term oral corticosteroids and with baseline FEV1 reversibilit

47 pite treatment with high doses of inhaled or oral corticosteroids and, in cluster D, reduced lung fun

48 ents who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticost

49 mesalazine, 50.4 (13.8) in those initiating oral corticosteroids, and 66.9 (13.7) in those initiatin

50 suppression comprising cell-cycle inhibitor, oral corticosteroids, and calcineurin inhibitor.

51 patients with asthma, including response to oral corticosteroids, and correlate these sites with exp

52 ing antibiotics, antihistamines, topical and oral corticosteroids, and epinephrine, have been used fo

53 ments of adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin were considered ind

54 Among patients with RA, DMARDs and/or use of oral corticosteroids appeared to be associated with herp

55 Oral corticosteroids are the first line of therapy for t

56 Oral corticosteroids as monotherapy are not associated w

57 and severe asthma exacerbations (ie, use of oral corticosteroids, asthma-related emergency departmen

58 These studies also suggest that oral corticosteroids at doses low enough for safe long-t

59 ); beta-blockers (beta = -1.02; P = .10) and oral corticosteroids (beta = 2.13; P = .07) were margina

60 s inversely associated with acute visits and oral corticosteroid bursts, whereas among those in homes

61 fference was observed in visual outcome with oral corticosteroids, but subjects treated with anti-VEG

62 Oral corticosteroids combined with antibiotics may be as

63 sion was 35% among patients who had received oral corticosteroids compared with 42% among those who h

64 es to reduce exacerbations and dependency on oral corticosteroids compared with placebo.

65 The lung function response to oral corticosteroids decreased with increasing sputum en

66 The average daily dose of inhaled or oral corticosteroids did not differ between the two grou

67 [CI], 0.53-0.77; P < 0.0001) and two or more oral corticosteroid dispensings (OR, 0.90; 95% CI, 0.81-

68 ma exacerbations were defined as two or more oral corticosteroid dispensings, asthma-related emergenc

69 thma-related emergency department visits and oral corticosteroid dispensings.

70 g-acting beta(2)-agonist but not maintenance oral corticosteroid does not preclude a robust clinical

71 placebo, allowed a significant reduction in oral corticosteroid dosages in patients with severe asth

72 pendent corticosteroid dose, age, sex, prior oral corticosteroid dose, prior topical corticosteroid u

73 Eligible patients who used oral corticosteroids during follow-up were identified an

74 ations (symptoms requiring a short course of oral corticosteroids) during the study was similar in th

75 eans 1.22 [1.06-1.41]; p=0.006), but reduced oral corticosteroid exposure (77.5 mg prednisone [240.5]

76 Eighty-one patients with CRSwNP took oral corticosteroids for 15 days.

77 Seventy-three patients with CRSwNP took oral corticosteroids for 15 days.

78 haled corticosteroids may be as effective as oral corticosteroids for acute asthma exacerbations.

79 To assess the effects of oral corticosteroids for acute lower respiratory tract i

80 To assess the clinical effectiveness of oral corticosteroids for acute sore throat in the absenc

81 In patients taking long-term oral corticosteroids for chronic lung disease, the relat

82 unity population (more than 50 years) taking oral corticosteroids for chronic lung disease.

83 orineural hearing loss has been treated with oral corticosteroids for more than 30 years.

84 f acyclovir, valacyclovir, or famcyclovir to oral corticosteroids for treatment of Bell palsy was ass

85 nts in the mesalazine group, 47 (33%) in the oral corticosteroid group, and 30 (21%) in the intraveno

86 nts in the mesalazine group, 21 (15%) in the oral corticosteroid group, and 52 (36%) in the intraveno

87 ed as any of the following: prescription for oral corticosteroids, >5 prescriptions for short acting

88 ct profile similar to, although milder than, oral corticosteroids has emerged.

89 Several new alternatives to oral corticosteroids have been evaluated in severe asthm

90 din analogues, calcium channel blockers, and oral corticosteroids have the largest relative effects.

91 ion with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common.

92 eeded to help reduce the need for continuous oral corticosteroids; however, there are currently very

93 Common therapeutic management included oral corticosteroids in 123 patients (93.2%), intravenou

94 rette smoking on the therapeutic response to oral corticosteroids in chronic stable asthma.

95 ed with improved outcomes when combined with oral corticosteroids in patients presenting within 72 ho

96 -agonists in asthma, the lack of efficacy of oral corticosteroids in preschool children with acute wh

97 tokine concentrations and their responses to oral corticosteroids in stable chronic asthma is unclear

98 The role of oral corticosteroids in treating patients with exacerbat

99 icosteroids among the 165 patients receiving oral corticosteroids, in prednisone equivalents, was 10

100 ultifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids, intravitreal ganciclovir and laser

101 The use of oral corticosteroids is associated with an increased ris

102 e of nonsteroidal antiinflammatory drugs and oral corticosteroids (</=10 mg/day prednisone or its equ

103 Treatment with oral corticosteroids may help to reduce the risk of CNVM

104 d point, defined as the need for a course of oral corticosteroids (n = 311) or a reduction in morning

105 428 children initiated mesalazine (n=136), oral corticosteroids (n=144), or intravenous corticoster

106 ents had nasal polyps that were resistant to oral corticosteroids (NP-CR).

107 ions (MENSA) and the percentage reduction in oral corticosteroid (OCS) dose (SIRIUS).

108 o reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year.

109 herence to inhaled corticosteroids (ICS) and oral corticosteroids (OCS) after discharge in adults hos

110 dation cohort (relatively high percentage on oral corticosteroids [OCS]).

111 Oral corticosteroids (OCSs) are recommended for severe w

112 Total doses of inhaled corticosteroids and oral corticosteroids (OCSs) were recorded, serum 25-hydr

113 been associated with continuous exposure to oral corticosteroids (OCSs).

114 oid therapy is safer than frequent bursts of oral corticosteroids on bone mineral accretion in this r

115 The effect of oral corticosteroids on FEV1 , Pc20, airway inflammation

116 ens clinically prescribed (antibiotics only, oral corticosteroids only, or both).

117 ealed associations with FVC % predicted, and oral corticosteroid or antileukotriene use.

118 litis who received concurrent treatment with oral corticosteroids or immunosuppressants.

119 nge, 11 to 50 years) who required inhaled or oral corticosteroids (or both) to receive either placebo

120 efined as no hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respirato

121 prior 3 months requiring hospital attention, oral corticosteroids, or both.

122 tal attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics.

123 he use of rescue therapy or long-term use of oral corticosteroids, or the dispensing of three or more

124 iene modifiers, short-acting beta2-agonists, oral corticosteroids, other bronchodilators, and no medi

125 djusting for the annual number of courses of oral corticosteroids (p trend = 0.007).

126 ls and an impaired lung function response to oral corticosteroids, particularly in asthmatic never sm

127 ised treatment with mesalazine (PUCAI 10-30) oral corticosteroids (PUCAI 35-60), or intravenous corti

128 termine the association between preadmission oral corticosteroid receipt and the development of acute

129 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% conf

130 ith increased asthma exacerbations requiring oral corticosteroids (repeated measures logistic regress

131 Oral corticosteroids should not be used for acute lower

132 safety events or the treatment effect in the oral corticosteroid subgroup.

133 th short, intermittent courses of inhaled or oral corticosteroids taken when symptoms worsen.

134 extractable results), of patients receiving oral corticosteroids, that compared vitamin D with eithe

135 er adjusting the model for annual courses of oral corticosteroids, the only confounder of note (OR 1.

136 nts with severe asthma who require long-term oral corticosteroid therapy are at risk of unwanted effe

137 ED visits, and 44% reduction in the need for oral corticosteroid therapy at 48 months, the model simu

138 ional regional corticosteroid injections and oral corticosteroid therapy for induction of remission.

139 te hospitalizations, ED visits, and need for oral corticosteroid therapy in childhood asthma for plan

140 ind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbatio

141 al therapy (topical, regionally injected, or oral corticosteroid therapy).

142 rate to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, t

143 s, 41% in ED visits, and 46% in the need for oral corticosteroid therapy.

144 vere asthma in spite of high-dose inhaled or oral corticosteroid therapy.

145 ncy department (ED) visits, and the need for oral corticosteroid therapy.

146 the current practice of prescribing low-dose oral corticosteroids to all patients with non-acidotic e

147 significant subset of patients that require oral corticosteroids to control symptoms.

148 months of completing ATT, inability to taper oral corticosteroids to less than 10 mg/d or topical cor

149 additional controller with or without daily oral corticosteroids) to patients aged 12 years or older

150 orally) or placebo, stratified by the use of oral corticosteroid treatment and bronchoscopy.

151 e smoking impairs the efficacy of short-term oral corticosteroid treatment in chronic asthma.

152 0005; hazard ratio [HR], 2.73), and previous oral corticosteroid treatment was associated with halvin

153 An oral corticosteroid treatment was started.

154 phone survey of patients receiving long-term oral corticosteroid treatment.

155 severe in patients with a history of chronic oral corticosteroid use (P = .01), drug (P = .04) or sev

156 linear models on brush samples demonstrated oral corticosteroid use as an important factor affecting

157 ly more frequent rescue-inhaler use, greater oral corticosteroid use, and a greater rate of hospitali

158 ergency department visits, hospitalizations, oral corticosteroid use, and the composite outcome of th

159 onal exhaled nitric oxide levels, along with oral corticosteroid use, that could predict the subtypes

160 nitric oxide levels, exacerbation rates, and oral corticosteroid use, whereas group 3 patients showed

161 ging immunomodulatory treatment, and current oral corticosteroid use.

162 httime symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits.

163 In both data sources, use of oral corticosteroids was associated with herpes zoster r

164 Initial treatment with topical and oral corticosteroids was ineffective.

165 chedule stratified by whether treatment with oral corticosteroids was required.

166 Carbogen inhalation and oral corticosteroids were also given.

167 Higher doses of preadmission oral corticosteroids were associated with a lower incide

168 g for prespecified confounders, preadmission oral corticosteroids were associated with a lower incide

169 Exacerbations identified by the need for oral corticosteroids were associated with more symptoms

170 Among ICU patients with sepsis, preadmission oral corticosteroids were independently associated with

171 In multivariable analyses, preadmission oral corticosteroids were not associated with in-hospita

172 Oral corticosteroids were prescribed for severe exacerba

173 The number of days on which oral corticosteroids were used was similar in the two gr

174 Prevention Program recommend the addition of oral corticosteroids, which are associated with substant

175 by analysing separately four small trials of oral corticosteroids with altogether 120 participants, i